Your browser doesn't support javascript.
loading
Olaparib: A Clinically Applied PARP Inhibitor Protects from Experimental Crohn's Disease and Maintains Barrier Integrity by Improving Bioenergetics through Rescuing Glycolysis in Colonic Epithelial Cells.
Kovács, Dominika; Vántus, Viola Bagóné; Vámos, Eszter; Kálmán, Nikoletta; Schicho, Rudolf; Gallyas, Ferenc; Radnai, Balázs.
  • Kovács D; Department of Biochemistry and Medical Chemistry, Medical School, University of Pécs, 7624 Pécs, Hungary.
  • Vántus VB; Department of Biochemistry and Medical Chemistry, Medical School, University of Pécs, 7624 Pécs, Hungary.
  • Vámos E; Department of Biochemistry and Medical Chemistry, Medical School, University of Pécs, 7624 Pécs, Hungary.
  • Kálmán N; Department of Biochemistry and Medical Chemistry, Medical School, University of Pécs, 7624 Pécs, Hungary.
  • Schicho R; Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz, Universitätsplatz 4, 8010 Graz, Austria.
  • Gallyas F; BioTechMed, 8010 Graz, Austria.
  • Radnai B; Department of Biochemistry and Medical Chemistry, Medical School, University of Pécs, 7624 Pécs, Hungary.
Oxid Med Cell Longev ; 2021: 7308897, 2021.
Article en En | MEDLINE | ID: mdl-34567413
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Ftalazinas / Piperazinas / Ácido Trinitrobencenosulfónico / Enfermedad de Crohn / Colitis / Colon Tipo de estudio: Etiology_studies / Prognostic_studies Límite: Animals Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Ftalazinas / Piperazinas / Ácido Trinitrobencenosulfónico / Enfermedad de Crohn / Colitis / Colon Tipo de estudio: Etiology_studies / Prognostic_studies Límite: Animals Idioma: En Año: 2021 Tipo del documento: Article